Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform to analyze results from its pivotal Phase III pediatric clinical trial.